Research Advances Of PD-1/PD-L1 In Colorectal Cancer

The programmed death 1(PD-1)and its ligand 1(PD-L1)are the focus of current immunotherapy.The combination of PD-1 and its ligand PD-L1 leads to the occurrence of T cell failure and immune escape in tumor microenvironment.Blocking PD-1 binding to PD-L1 is an effective therapeutic target.Monoclonal antibodies against PD-1 / PD-L1 pathways have been approved by the USA FDA for clinical trials and have been identified in malignant melanoma,lung cancer,bladder cancer,gastric cancer,Hodgkin's lymphoma,breast cancer having achieved remarkable results.The current treatment in colorectal cancer also showed a good effect.At present,the research progress of the molecular structure and expression of PD-1/PD-L1,the biological function of tumor,PD-1/PD-L1 immunohistochemistry testing,the clinical features and prognosis of colorectal cancer,the characteristics of the colorectal cancer microenvironment,PD-1 /PD-L1 inhibitor and drug resistance in colorectal cancer made a review.